Top Markets
#1 Islamic Coin Islamic Coin +151.54%
#2 Akedo Akedo +66.39%
#3 Glidr Glidr +51.75%
#4 DOVU DOVU +48.78%
#5 Velvet Velvet +41.51%
#6 Cross Cross +35.02%
#7 Black Phoenix Black Phoenix +34.13%
#8 Cap Cap +20.45%
#9 DoubleZero DoubleZero +15.18%
#10 GRVT Token GRVT Token +9.99%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
XORTX Therapeutics Inc. XORTX Therapeutics Inc.

XORTX Therapeutics Inc.

XRTX
Rank in Stocks #39281
Based in Vancouver, Canada, XORTX Therapeutics Inc. is a biopharmaceutical firm... Based in Vancouver, Canada, XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering and bringing to market treatments for a variety of conditions, including progressive kidney disorders, diabetes, insulin resistance, metabolic syndrome, and infections. The company's pipeline includes XRx-008, a late-stage clinical program addressing autosomal dominant polycystic kidney disease; XRx-101, an agent designed to reduce uric acid levels in COVID-19 patients to prevent acute kidney injury and its associated health issues; and XRx-221, a series of xanthine oxidase inhibitor candidates aimed at treating diabetic nephropathy. Furthermore, XORTX Therapeutics collaborates with the Icahn School of Medicine to research the occurrence of acute kidney injury and elevated uric acid in patients hospitalized with COVID-19.
Share Price
$2.06
Last synced: 2026-08-11
Market Cap
$572.30K
Change (1 day)
0.00%
Change (1 year)
-90.38%
Country
CA
Trade XORTX Therapeutics Inc. (XRTX)

Category

Healthcare
Revenue for XORTX Therapeutics Inc. (XRTX)
Revenue in Aug 2026 TTM: 0
According to XORTX Therapeutics Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for XORTX Therapeutics Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE